Procter & Gamble Health Ltd (PGHL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Procter & Gamble Health Ltd on NSE and BSE, with an AI summary of each filing.
Press release for the unaudited financial results for the quarter ended September 30, 2026.
Press Release · 02 Nov 2026, 8:23 pm
Procter & Gamble Health Reports Strong Q2 Results with 26% PAT Growth Procter & Gamble Health Ltd. reported robust Q2 financial results for the period ended 30th Sep'26. Sales rose 18% YoY to ₹376 crore, supported by strong brand fundamentals, improved retail execution, favorable consumer response to new innovations, and enhanced go-to-market execution. Reported Profit After Tax (PAT) climbed 26% YoY to ₹112 crore, driven by top-line expansion and sustained productivity gains across the value chain. Growth across key healthcare and VMS brands reflected rising consumer demand for preventive healthcare.
Outcome of Board Meeting for the Quarter Ended September 30, 2026
Financial Result · 02 Nov 2026, 8:19 pm
Procter & Gamble Health Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 02 Nov 2026, 8:15 pm
Outcome of the Board Meeting for the Quarter and half year ended September 30 , 2026.
Outcome · 02 Nov 2026, 8:13 pm
Procter & Gamble Health Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakhs) ■ Revenue: 38,249 (+17.7% YoY | +5.2% QoQ) ■ EBITDA: 15,237 (+26.7% YoY | +53.0% QoQ) ■ EBITDA Margin (%): 39.8 (+282 bps YoY | +1245 bps QoQ) ■ PAT: 11,151 (+25.9% YoY | +16.0% QoQ) ■ EPS (INR): 67.2 (+25.9% YoY | +73.3% QoQ)
PROCTER & GAMBLE HEALTH LIMITED has informed the Exchange about Board Meeting to be held on 02-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 02 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 02 Nov 2026, 5:30 am
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve unaudited financial ....
Intimation · 02 Nov 2026, 5:30 am
Procter & Gamble Health Schedules Board Meeting on 2nd Nov'26 to Consider Q2 Results Procter & Gamble Health Limited announced that its Board of Directors is scheduled to meet on 2nd Nov'26. The board will, inter alia, consider and approve the company's unaudited financial results for the quarter and half year ended 30th Sep'26, in compliance with Regulation 29 of the SEBI Listing Regulations.
Stock Exchange is informed about an update on Ease of doing Investment - Special Window for Transfer and Dematerialization.
Others (Uncategorized) · 19 Sept 2026, 1:08 am
SEBI Extends Special Window for Physical Share Transfers to Feb'27 Procter & Gamble Health Limited informed stock exchanges that SEBI extended the timeline of the special window for re-lodging physical share transfer requests until 4th Feb'27. The facility applies strictly to transfer deeds submitted prior to 1st Apr'19 that were returned, rejected, or unaddressed due to process or document deficiencies. Transfers under this window will be processed exclusively in dematerialized form. Eligible shareholders must submit requests and requisite documentation to the company’s RTA, KFin Technologies Limited, or the registered office.
The shareholders at their AGM held on September 3, 2026 approved the re-appointment of Mr. S. Madhavan as Independent Director of the Company for a period of 5 years effective November 15, 2026.
Annual General Meeting · 04 Sept 2026, 10:49 pm
Scrutinizers Report and E-Voting results for the Annual General Meeting held on September 3, 2026.
Annual General Meeting · 04 Sept 2026, 10:44 pm
Enclosed a summary of proceedings of the Annual General Meeting held today, viz., September 3, 2026.
Annual General Meeting · 03 Sept 2026, 11:16 pm
The 59th Annual General Meeting of the Company is scheduled on Thursday, September 3, 2026 at 2:30 PM.
Annual General Meeting · 12 Aug 2026, 10:23 pm
The BRSR Report for the Financial Year ended March 31, 2026 is enclosed.
Others (Uncategorized) · 12 Aug 2026, 10:18 pm
P&G Health's FY26 Business Responsibility and Sustainability Report Procter & Gamble Health submitted its Business Responsibility & Sustainability Report for the year ended 31 Mar'26. Exports contributed 8.24% to total turnover. FY26 permanent employee turnover was 5.90%, a notable improvement from 18.73% in FY24. In FY26, total energy consumption rose to 46,995 GJ from 43,509 GJ YoY, while water withdrawal decreased to 55,888 kilolitres from 57,909 kilolitres. Scope 1 & 2 GHG emissions were 3,338 metric tonnes of CO2 equivalent, down from 4,536 tonnes in FY25, with emission intensity remaining stable at 0.05 MT per ₹ lakh turnover.
Annual Report for the Financial Year 2025-26 is enclosed for the Annual General Meeting scheduled on Thursday September 3, 2026.
Others (Uncategorized) · 12 Aug 2026, 10:14 pm
Enclosed herewith is the Annual Report for the Financial Year 2025-26 and Notice calling the 59th Annual General Meeting of the Company, scheduled on Thursday, September 3, 2026 at 2:30 p.m.
Annual General Meeting · 12 Aug 2026, 10:08 pm
Record Date for Purpose of Dividend
Dividend · 11 Aug 2026, 12:23 am
P&G Health Revises AGM and Final Dividend Record Date Procter & Gamble Health Ltd. has revised the schedule for its 59th Annual General Meeting (AGM) to Thu, 3rd Sep'26. The company has also set a new record date of Thu, 27th Aug'26 for determining shareholder eligibility for the final dividend for FY 2025-26. The dividend payment, subject to shareholder approval at the AGM, is scheduled for 27th Sep'26. This notice updates the previous communication from 26th May'26.
Press Release on the Unaudited Financial Results for the Quarter ended June 30, 2026.
Press Release · 06 Aug 2026, 7:35 pm
P&G Health Q1FY27: Sales Rise 7%; PAT Jumps 45% on One-Time Gain Procter & Gamble Health reported Q1FY27 results for the quarter ended 30 Jun'26, with sales of ₹356 crores, up 7% YoY, driven by strong brand fundamentals and retail execution. Reported Profit After Tax (PAT) stood at ₹96 crores, a 45% YoY increase, boosted by a one-time gain from an asset sale. Excluding this one-time item, operational PAT was ₹72 crores, up 9% YoY. The growth reflects improved supply chain capabilities and consumer response to new innovations.
Unaudited Financial Results for the Quarter ended June 30, 2026
Financial Result · 06 Aug 2026, 7:33 pm
P&G Health Q1FY27 Results Boosted by Exceptional Gain from Property Sale Procter & Gamble Health reported a 45.3% YoY rise in Net Profit to ₹96.15 crore for the quarter ended Jun'26, driven by an exceptional gain of ₹31.80 crore from a property sale. Revenue from Operations grew 7.4% YoY to ₹363.71 crore. Total expenses increased 6.4% YoY to ₹270.27 crore. Profit Before Tax stood at ₹129.12 crore, up 45.4% YoY. The Basic EPS after exceptional items was ₹57.92, a significant increase from ₹39.87 in the corresponding quarter last year.
Outcome of Board Meeting.
Outcome · 06 Aug 2026, 7:30 pm
Procter & Gamble Health Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakhs) ■ Revenue: 36,371 (+7.4% YoY | -1.8% QoQ) ■ EBITDA: 9,960 (+10.3% YoY | -26.5% QoQ) ■ EBITDA Margin (%): 27.4 (+72 bps YoY | -922 bps QoQ) ■ PAT: 9,615 (+45.3% YoY | +1.6% QoQ) ■ EPS (INR): 38.8 (-2.8% YoY | -32.0% QoQ)
Dear Sir/Madam, Please find attached intimation regarding change in Company''s Annual General Meeting date for the Financial Year 2025-26 and record date for purpose of AGM/distribution ....
Annual General Meeting · 15 Jul 2026, 11:55 pm
Dear Sir, Please find attached communication in respect of deduction of TDS on the amount of final dividend income from the Company, if approved by the shareholders at the ensuing AGM.
Annual General Meeting · 26 Jun 2026, 11:50 pm
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve Dear Sir, In terms ....
Intimation · 06 Aug 2026, 5:30 am
Pursuant to regulation 30 of the SEBI (LODR) Regulations, 2015, we hereby inform you regarding changes in the Senior Management Personnel of the Company shall take place effective July 1, 2026.
Change in Management · 26 Jun 2026, 1:31 am
P&G Health Announces Senior Management Reshuffle P&G Health announced senior management changes effective Jul 1, '26. Mr. Abhijit Roy will become Sales Leader (South & East) and Exports Leader. Mr. M. Padmakar Rao is appointed Sales Leader (North & West) and Institutional Business Leader. Mr. Nilesh Barbade will assume the role of Sales Leader (Trade). Concurrently, Mr. Shine Matthew Sunny has been appointed as the Marketing Strategy and Planning Leader, Commercial Excellence & E-commerce Leader. The first three are internal role changes, while the last is a new appointment to senior management.
The Company has informed the Stock Exchange regarding the transcript and link to the recording of the analyst/institutional investors meeting held earlier today.
Audio / Video · 19 Jun 2026, 2:36 am
P&G Health Highlights Strong FY26 Performance and Growth Strategy For FY ending 31 Mar'26, Procter & Gamble Health reported sales near ₹1,400 crore (+16% YoY) and PAT of ₹327 crore (+30% YoY), driven by its integrated growth strategy. Key brands Neurobion and Livogen grew around 20%. The company launched three innovations—Livogen Iron Gummies, Neurobion Nerve Pain Relief Cream, and Evion L5000—which collectively added early single-digit growth. Management highlighted a ₹35 crore saving from productivity initiatives and consistent high single-digit average sales growth over the past five years.
The Company has informed the Stock Exchange regarding the Presentation of the Analyst/Institutional investor meet scheduled to be held today.
Intimation · 18 Jun 2026, 3:02 pm